180 Life Sciences (NASDAQ:ATNF – Get Rating) and Antibe Therapeutics (OTCMKTS:ATBPD – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
Institutional & Insider Ownership
15.3% of 180 Life Sciences shares are held by institutional investors. 15.2% of 180 Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares 180 Life Sciences and Antibe Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|180 Life Sciences||N/A||N/A||-$38.73 million||($7.20)||-0.17|
|Antibe Therapeutics||$7.51 million||19.43||-$14.54 million||($0.60)||-0.63|
Volatility & Risk
180 Life Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
This table compares 180 Life Sciences and Antibe Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|180 Life Sciences||N/A||-119.88%||-85.65%|
This is a summary of recent recommendations for 180 Life Sciences and Antibe Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|180 Life Sciences||0||0||1||0||3.00|
180 Life Sciences beats Antibe Therapeutics on 7 of the 11 factors compared between the two stocks.
About 180 Life Sciences
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
About Antibe Therapeutics
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.